Scarica l'app Stockscreener
5.19
0.00%
0.00
Dopo l'orario di chiusura:
5.10
-0.09
-1.73%
Precedente Chiudi:
$5.19
Aprire:
$5.27
Volume 24 ore:
1.04M
Relative Volume:
0.49
Capitalizzazione di mercato:
$923.10M
Reddito:
-
Utile/perdita netta:
$-45.44M
Rapporto P/E:
-14.83
EPS:
-0.35
Flusso di cassa netto:
$-42.28M
1 W Prestazione:
-5.81%
1M Prestazione:
-17.36%
6M Prestazione:
+45.38%
1 anno Prestazione:
+110.12%
Intervallo 1D:
$5.07
$5.36
Intervallo di 1 settimana:
$5.07
$5.78
Portata 52W:
$1.33
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Nome
Compass Therapeutics Inc
Settore
Industria
Telefono
617-500-8099
Indirizzo
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.19 | 923.10M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-13 | Iniziato | Craig Hallum | Buy |
| 2026-01-05 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Canaccord Genuity | Buy |
| 2025-12-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2025-04-02 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Iniziato | Guggenheim | Buy |
| 2025-02-19 | Iniziato | Piper Sandler | Overweight |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Iniziato | Jefferies | Buy |
| 2023-01-27 | Iniziato | Stifel | Buy |
| 2022-05-23 | Ripresa | H.C. Wainwright | Buy |
| 2022-03-15 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-01-19 | Iniziato | B. Riley Securities | Buy |
| 2021-12-22 | Iniziato | Raymond James | Outperform |
| 2021-12-20 | Iniziato | SVB Leerink | Outperform |
| 2021-12-15 | Iniziato | Wedbush | Outperform |
Mostra tutto
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
Here's why Compass Therapeutics, Inc. (CMPX) is a great momentum stock to buy - MSN
Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026 - Meyka
Is Compass Therapeutics' (CMPX) New ESOP Shelf Offering Reframing Its Equity-Funded R&D Strategy? - simplywall.st
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Compass Therapeutics Inc celebrates women leadership driving innovation in science and therapy development - Traders Union
Compass Therapeutics stock rating reaffirmed at Citizens on trial progress By Investing.com - Investing.com Canada
What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy - Yahoo Finance
HC Wainwright Has Positive Estimate for CMPX FY2026 Earnings - MarketBeat
A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance - Sahm
What is HC Wainwright's Estimate for CMPX Q1 Earnings? - MarketBeat
Jefferies raises Compass Therapeutics stock price target on trial progress By Investing.com - Investing.com Australia
Jefferies raises Compass Therapeutics stock price target on trial progress - Investing.com
Compass Therapeutics stock holds Outperform at William Blair ahead of trial data - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating By Investing.com - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating - Investing.com
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - Investing News Network
Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compass Therapeutics' Q4 Net Loss Narrows - marketscreener.com
Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss - marketscreener.com
Compass Therapeutics' 2025 net loss widens as R&D costs jump - TradingView
Compass Therapeutics 10-K: $0.0M Revenue, $(0.42) EPS on $(66.5)M Net Loss - TradingView
Cancer trial hits survival milestone as Compass funds work to 2028 - Stock Titan
How Palo Alto’s New Stake and Rising Institutional Ownership At Compass Therapeutics (CMPX) Has Changed Its Investment Story - simplywall.st
Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market - Yahoo Finance
Monashee Investment Management Boosts Stake in Compass Therapeutics - National Today
Signal Recap: Does Compass Therapeutics Inc have a competitive edgeQuarterly Performance Summary & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Monashee Investment Management LLC Has $4.38 Million Stake in Compass Therapeutics, Inc. $CMPX - MarketBeat
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a 130% Potential Upside in Biotech - DirectorsTalk Interviews
Compass Therapeutics earnings on deck as pivotal cancer data looms By Investing.com - Investing.com Canada
Compass Therapeutics earnings on deck as pivotal cancer data looms - Investing.com
Compass Therapeutics Inc. expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Zacks.com Spotlights Orla Mining, FIGS, and Compass Therapeutics - Intellectia AI
Is Compass Therapeutics Inc. stock forming a cup and handleJuly 2025 Retail & Reliable Entry Point Trade Alerts - mfd.ru
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know - TipRanks
Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday - MarketBeat
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Support Test: Can Compass Therapeutics Inc. sustain its profitabilityOil Prices & Weekly Return Optimization Alerts - mfd.ru
Bearish Setup: Will Compass Therapeutics Inc stock go up in YEAREarnings Miss & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Compass Therapeutics (NASDAQ:CMPX) Raised to "Hold" at Wall Street Zen - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Research Coverage Started at Craig Hallum - Defense World
Compass Therapeutics (NASDAQ:CMPX) Raised to “Hold” at Wall Street Zen - Defense World
How much upside does Compass Therapeutics Inc. haveWall Street Watch & Daily Stock Momentum Reports - mfd.ru
Craig-Hallum initiates coverage on Compass Therapeutics stock with Buy rating - Investing.com Canada
Compass Therapeutics stock rises after Craig-Hallum initiates coverage with Buy - Investing.com Canada
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Craig Hallum - MarketBeat
Compass Therapeutics Inc Azioni (CMPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):